Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus IBUPROFEN SODIUM.
DUEXIS vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category C
Category D/X
NSAID/H2 Antagonist Combination
NSAID